1. Home
  2. TMDX vs AGIO Comparison

TMDX vs AGIO Comparison

Compare TMDX & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TMDX
  • AGIO
  • Stock Information
  • Founded
  • TMDX 1998
  • AGIO 2007
  • Country
  • TMDX United States
  • AGIO United States
  • Employees
  • TMDX N/A
  • AGIO N/A
  • Industry
  • TMDX Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • AGIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • TMDX Health Care
  • AGIO Health Care
  • Exchange
  • TMDX Nasdaq
  • AGIO Nasdaq
  • Market Cap
  • TMDX 2.4B
  • AGIO 2.0B
  • IPO Year
  • TMDX 2019
  • AGIO 2013
  • Fundamental
  • Price
  • TMDX $71.95
  • AGIO $35.22
  • Analyst Decision
  • TMDX Buy
  • AGIO Buy
  • Analyst Count
  • TMDX 11
  • AGIO 7
  • Target Price
  • TMDX $116.10
  • AGIO $56.33
  • AVG Volume (30 Days)
  • TMDX 1.3M
  • AGIO 621.1K
  • Earning Date
  • TMDX 02-27-2025
  • AGIO 02-13-2025
  • Dividend Yield
  • TMDX N/A
  • AGIO N/A
  • EPS Growth
  • TMDX N/A
  • AGIO N/A
  • EPS
  • TMDX 0.94
  • AGIO 11.64
  • Revenue
  • TMDX $401,090,000.00
  • AGIO $36,498,000.00
  • Revenue This Year
  • TMDX $81.61
  • AGIO $166.22
  • Revenue Next Year
  • TMDX $22.52
  • AGIO $98.36
  • P/E Ratio
  • TMDX $76.78
  • AGIO $3.03
  • Revenue Growth
  • TMDX 109.09
  • AGIO 36.07
  • 52 Week Low
  • TMDX $55.00
  • AGIO $27.14
  • 52 Week High
  • TMDX $177.37
  • AGIO $62.58
  • Technical
  • Relative Strength Index (RSI)
  • TMDX 52.52
  • AGIO 54.02
  • Support Level
  • TMDX $66.81
  • AGIO $33.25
  • Resistance Level
  • TMDX $80.00
  • AGIO $34.86
  • Average True Range (ATR)
  • TMDX 4.14
  • AGIO 1.33
  • MACD
  • TMDX 0.57
  • AGIO 0.37
  • Stochastic Oscillator
  • TMDX 48.74
  • AGIO 97.99

About TMDX TransMedics Group Inc.

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Share on Social Networks: